The role of Toujeo®, insulin glargine U‐300, in the treatment of diabetes mellitus
| Autor: | Courtney S. Davis, Meagan A. Brown, Joshua W. Fleming, Laurie W. Fleming |
|---|---|
| Rok vydání: | 2016 |
| Předmět: |
medicine.medical_specialty
Package insert medicine.medical_treatment MEDLINE Insulin Glargine 030209 endocrinology & metabolism 030204 cardiovascular system & hematology Hypoglycemia Weight Gain 03 medical and health sciences 0302 clinical medicine Diabetes mellitus Internal medicine Diabetes Mellitus Humans Hypoglycemic Agents Medicine General Nursing business.industry Insulin glargine Insulin nutritional and metabolic diseases General Medicine medicine.disease Clinical trial Basal (medicine) business medicine.drug |
| Zdroj: | Journal of the American Association of Nurse Practitioners. 28:503-509 |
| ISSN: | 2327-6924 |
| DOI: | 10.1002/2327-6924.12357 |
| Popis: | Purpose The purpose of this article is to educate nurse practitioners about the role of Toujeo®, insulin glargine U-300 (Gla-300), which is a new option for the treatment of diabetes mellitus. Data sources A comprehensive literature search was conducted using MEDLINE with the key terms: insulin glargine 300, Toujeo, Gla-300, and EDITION for clinical trial data. Other resources included package inserts, drug information websites, and the World Health Organization (WHO). Conclusions Gla-300 appears to be a safe and effective option for basal insulin therapy. In clinical trials, it was shown to be equally efficacious as Gla-100 with fewer episodes of hypoglycemia and slightly less weight gain, and subjects receiving Gla-300 required approximately 10 units more basal insulin to obtain the same hemoglobin A1c (HbA1c) as subjects receiving Gla-100. Implications for practice This new basal therapy option represents a potential advantage for patients who require higher doses of insulin because of the higher concentration of Gla-300. The lower incidence of hypoglycemia and more predictable pharmacokinetics could offer a significant therapeutic benefit in difficult-to-control patients with diabetes mellitus. The biggest disadvantage of this product is the slightly higher insulin dosage that is required to improve and/or maintain patients’ HbA1c. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text